Intravesical Thermochemotherapy With Mitomycin-c

Launched by TC ERCIYES UNIVERSITY · Oct 1, 2018

Keywords

ClinConnect Summary

Before the application of TCT, complete transurethral bladder tumour resection (TURBT) was performed. RE-TURBT was conducted within 4 weeks for patients with initial T1 pathology. The first TCT instillation was applied at 1mo following the TURBT or the RE-TURBT.

Thermochemotherapy application and treatment schedule:

The bladder wall TCT (BWT) system (Elmedical Ltd, Hod-Hasharon, Israel) was used as a conductive heating modality. MMC (40 mg; MMC Kyowa Hakko Kogyo Co., Ltd., Tokyo, Japan) was mixed with 50 mL of 0.9% saline solution and applied using a disposable silicone 20Fr 3-way TCT cat...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • newly diagnosed or followed as recurrent intermediate-risk non muscle invasive non muscle invasive bladder cancer according to the criteria of European Association of Urology.
• • newly diagnosed or followed as recurrent high-risk non muscle invasive non muscle invasive bladder cancer according to the criteria of European Association of Urology.
• • pathology of urothelial carcinoma
• Exclusion Criteria:
• • Low bladder capacity (\<150ml)
• • increased post voiding residual urine (\>150ml)
• • untreatable or uncontrollable urinary tract infection
• • history of urethral stricture
• • presence of bladder diverticula larger than 1 cm
• • pathology other than urothelial carcinoma
• • WHO (World Health Organization) performance status \> 2
• • upper urinary tract urothelial carcinoma diagnosis